Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2017 1
2018 3
2019 5
2020 1
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

9 results
Results by year
Filters applied: . Clear all
Page 1
Modulators of CXCR4 and CXCR7/ACKR3 Function.
Adlere I, Caspar B, Arimont M, Dekkers S, Visser K, Stuijt J, de Graaf C, Stocks M, Kellam B, Briddon S, Wijtmans M, de Esch I, Hill S, Leurs R. Adlere I, et al. Among authors: arimont m. Mol Pharmacol. 2019 Dec;96(6):737-752. doi: 10.1124/mol.119.117663. Epub 2019 Sep 23. Mol Pharmacol. 2019. PMID: 31548340 Review.
Antibodies Targeting Chemokine Receptors CXCR4 and ACKR3.
Bobkov V, Arimont M, Zarca A, De Groof TWM, van der Woning B, de Haard H, Smit MJ. Bobkov V, et al. Among authors: arimont m. Mol Pharmacol. 2019 Dec;96(6):753-764. doi: 10.1124/mol.119.116954. Epub 2019 Sep 3. Mol Pharmacol. 2019. PMID: 31481460 Review.
Structural Analysis of Chemokine Receptor-Ligand Interactions.
Arimont M, Sun SL, Leurs R, Smit M, de Esch IJP, de Graaf C. Arimont M, et al. J Med Chem. 2017 Jun 22;60(12):4735-4779. doi: 10.1021/acs.jmedchem.6b01309. Epub 2017 Mar 10. J Med Chem. 2017. PMID: 28165741 Free PMC article. Review.
CXCR4-targeting nanobodies differentially inhibit CXCR4 function and HIV entry.
Van Hout A, Klarenbeek A, Bobkov V, Doijen J, Arimont M, Zhao C, Heukers R, Rimkunas R, de Graaf C, Verrips T, van der Woning B, de Haard H, Rucker JB, Vermeire K, Handel T, Van Loy T, Smit MJ, Schols D. Van Hout A, et al. Among authors: arimont m. Biochem Pharmacol. 2018 Dec;158:402-412. doi: 10.1016/j.bcp.2018.10.015. Epub 2018 Oct 17. Biochem Pharmacol. 2018. PMID: 30342024
Advanced fluorescence microscopy reveals disruption of dynamic CXCR4 dimerization by subpocket-specific inverse agonists.
Işbilir A, Möller J, Arimont M, Bobkov V, Perpiñá-Viciano C, Hoffmann C, Inoue A, Heukers R, de Graaf C, Smit MJ, Annibale P, Lohse MJ. Işbilir A, et al. Among authors: arimont m. Proc Natl Acad Sci U S A. 2020 Nov 17;117(46):29144-29154. doi: 10.1073/pnas.2013319117. Epub 2020 Nov 4. Proc Natl Acad Sci U S A. 2020. PMID: 33148803 Free PMC article.
Structure-based exploration and pharmacological evaluation of N-substituted piperidin-4-yl-methanamine CXCR4 chemokine receptor antagonists.
Adlere I, Sun S, Zarca A, Roumen L, Gozelle M, Viciano CP, Caspar B, Arimont M, Bebelman JP, Briddon SJ, Hoffmann C, Hill SJ, Smit MJ, Vischer HF, Wijtmans M, de Graaf C, de Esch IJP, Leurs R. Adlere I, et al. Among authors: arimont m. Eur J Med Chem. 2019 Jan 15;162:631-649. doi: 10.1016/j.ejmech.2018.10.060. Epub 2018 Oct 30. Eur J Med Chem. 2019. PMID: 30476826
4-(3-Aminoazetidin-1-yl)pyrimidin-2-amines as High-Affinity Non-imidazole Histamine H3 Receptor Agonists with in Vivo Central Nervous System Activity.
Wágner G, Mocking TAM, Arimont M, Provensi G, Rani B, Silva-Marques B, Latacz G, Da Costa Pereira D, Karatzidou C, Vischer HF, Wijtmans M, Kieć-Kononowicz K, de Esch IJP, Leurs R. Wágner G, et al. Among authors: arimont m. J Med Chem. 2019 Dec 12;62(23):10848-10866. doi: 10.1021/acs.jmedchem.9b01462. Epub 2019 Nov 20. J Med Chem. 2019. PMID: 31675226 Free PMC article.
Nanobody-Fc constructs targeting chemokine receptor CXCR4 potently inhibit signaling and CXCR4-mediated HIV-entry and induce antibody effector functions.
Bobkov V, Zarca AM, Van Hout A, Arimont M, Doijen J, Bialkowska M, Toffoli E, Klarenbeek A, van der Woning B, van der Vliet HJ, Van Loy T, de Haard H, Schols D, Heukers R, Smit MJ. Bobkov V, et al. Among authors: arimont m. Biochem Pharmacol. 2018 Dec;158:413-424. doi: 10.1016/j.bcp.2018.10.014. Epub 2018 Oct 17. Biochem Pharmacol. 2018. PMID: 30342023 Free article.